Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07027878 · ClinicalTrials.gov registry record
JETi Lower Extremity Venous Thrombosis
A clinical trial of Venous Thrombosis, sponsored by Abbott Medical Devices.
- Active
- Registry status
- 121
- Enrollment target
- 20
- Study locations
NCT07027878: Active study of Venous Thrombosis, sponsored by Abbott Medical Devices.
NCT07027878 is a study of Venous Thrombosis that is active but no longer recruiting, run by Abbott Medical Devices. The registered enrollment target is 121 participants, below the 1,112-participant average among 9 other Venous Thrombosis trials with a reported enrollment target (89% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07027878, a study of Venous Thrombosis, is active but no longer recruiting, sponsored by Abbott Medical Devices.
- ACTIVE NOT RECRUITING
- Registry status
- 121 participants
- Enrollment target
- 20
- Study locations
Study Summary
The JETi Registry is a prospective, single-arm, multicenter study to collect real-world data on the safety, performance, and clinical benefits of the JETi System for the treatment of acute and subacute thrombosis in the peripheral vasculature. This is a post-market study that will register approximately 280 subjects at approximately 30 centers globally. Subjects participating in this registry will be followed through their 12-month follow up visit.
Primary Outcome
The percent of treated vessel(s) with ≥ 75% venous thrombus reduction from pre-JETi venogram to final venogram (post-JETi and after any/all adjunctive therapies to treat underlying culprit lesions) via modified Marder score. Marder Score Reduction is calculated using the formula below: \[(Pre-JETi Marder Score - final Marder Score) / Pre-JETi Marder Score\] x 100. Modified Marder Score is a calculation based on summation of gradient thrombus burden at the following venous segments: iliac, comm
Conditions Studied
Interventions
- DEVICE JETi lower extremity venous thrombosis
Study Locations (20)
California
- PIH Good Samaritan - Los Angeles
- Cedars Sinai Medical Center - Los Angeles
- Stanford University Hospital and Clinics - Palo Alto
Colorado
- University of Colorado - Aurora
- ClinRé - Thornton
New York
- Weill Cornell Medicine - New York
- Mount Sinai Hospital - New York
Oklahoma
- Ascension St. John Jane Phillips - Bartlesville
- Hightower Clinical - Oklahoma City
Arizona
- HonorHealth - Scottsdale
Arkansas
- Arkansas Heart Hospital - Little Rock
Indiana
- St. Mary Medical Center - Hobart
Iowa
- Midwest Cardiovascular Research Foundation - Davenport
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2020-03-06 |
| Est. Completion | 2025-08 |
What the registry record for NCT07027878 still lists
NCT07027878 is an observational study that tracks outcomes without assigning an intervention. The registered 121 participants enrollment target is mid-sized for trials with a published cap, below the 1,112-participant average among 9 other Venous Thrombosis trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Venous Thrombosis appearing as the primary indexed condition, and to 1 intervention - of which JETi lower extremity venous thrombosis is the first listed.
NCT07027878 names 20 study sites across 15 states, led by California, Colorado, New York.
Frequently Asked Questions
What is clinical trial NCT07027878 about?
NCT07027878 is a clinical study titled "JETi Lower Extremity Venous Thrombosis". The JETi Registry is a prospective, single-arm, multicenter study to collect real-world data on the safety, performance, and clinical benefits of the JETi System for the treatment of acute and subacute thrombosis in the peripheral vasculature. This is a post-market study that will register approxima...
What is the current status of trial NCT07027878?
This trial is currently active not recruiting. The enrollment target is 121 participants. The study started on 2020-03-06. Estimated completion is 2025-08.
What conditions does trial NCT07027878 study?
This clinical trial studies the following conditions: Venous Thrombosis.
What interventions are being tested in trial NCT07027878?
The interventions under investigation include: JETi lower extremity venous thrombosis (DEVICE).
Who is sponsoring clinical trial NCT07027878?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07027878 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Venous Thrombosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07027878's enrollment target sits among peer trials
121 6th of 9 higher than 4 of 9 other Venous Thrombosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Venous Thrombosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Registry of AngioJet Use in the Peripheral Vascular System
COMPLETED
-
Peripherally Inserted Central Catheter (PICC) Thrombosis: Reverse Taper Versus Non-tapered Catheters
COMPLETED · NA
-
Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism
COMPLETED · Phase 3
-
Nifedipine vs Placebo for Maintenance Tocolysis of Preterm Labor.
COMPLETED · NA
-
Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism
COMPLETED · Phase 3
-
Investigation Into the Therapeutic Dosage of Fondaparinux Sodium, a Medication Used to Prevent Blood Clots in Morbidly Obese Volunteers
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03476681 · 121 participants · Phase 1
Study of NEO-201 in Solid Tumors Expansion Cohorts
- NCT04655118 · 121 participants · Phase 2
Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis
- NCT04676802 · 121 participants · Phase 2
Pain Relief After Trapeziectomy: Ibuprofen & Acetaminophen Versus Oxycodone
- NCT05169515 · 121 participants · Phase 1
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI